Owlet, Inc.
- Open
- 4.99
- Day high
- 5.13
- Day low
- 4.91
- Prev close
- 4.99
- Volume
- 210K
- Mkt cap
- $146M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.7
- P/S
- 1.3
- Yield
- —
- Per share
- —
Owlet, Inc. (OWLT) is a Healthcare company listed on NYSE. The stock is down 36% over the past year.
Owlet, Inc. (OWLT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
OWLT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.09 | $-0.05 | +44.4% | $34M | +6.9% |
| May 7, 2026 | $-0.18 | $-0.09 | +50.0% | $23M | +8.0% |
| Mar 5, 2026 | $-0.14 | $-0.03 | +78.5% | $27M | +1.1% |
| Nov 13, 2025 | $-0.23 | $0.03 | +113.0% | $32M | +23.0% |
| Aug 7, 2025 | $-0.21 | $-0.05 | +76.2% | $26M | +0.3% |
| May 8, 2025 | $-0.27 | $-0.07 | +74.1% | $21M | -4.7% |
| Mar 4, 2025 | $-0.51 | $-0.07 | +86.3% | $21M | +23.8% |
| Mar 7, 2024 | $-0.04 | $-0.12 | -200.0% | $21M | +13.4% |
| Nov 13, 2023 | $-0.36 | $-0.70 | -94.4% | $9M | -56.6% |
| Aug 14, 2023 | $-0.72 | $-0.56 | +22.2% | $13M | -9.0% |
| May 11, 2023 | $-1.26 | $-1.12 | +11.1% | $11M | -1.7% |
| Mar 15, 2023 | $-2.24 | $-1.96 | +12.5% | $12M | -7.1% |
OWLT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | BURKE ZANE Mdirector | Grant | 26,785 | — |
| Aug 21, 2026 | Stoll Marc Fdirector | Grant | 18,996 | — |
| Aug 21, 2026 | Stoll Marc Fdirector | Grant | 26,785 | — |
| Aug 21, 2026 | BURKE ZANE Mdirector | Grant | 18,996 | — |
| Aug 14, 2026 | Gonzales Melissadirector | Grant | 26,785 | — |
| Aug 14, 2026 | Kim John C.director | Grant | 26,785 | — |
| Aug 14, 2026 | Durr Lauradirector | Grant | 26,785 | — |
| Jul 9, 2026 | Workman Kurtofficer: President & CEO | Tax | 21,001 | $5.91 |
| May 1, 2026 | Durr Lauradirector | Grant | 18,996 | — |
| Apr 30, 2026 | Kim John C.director | Grant | 18,996 | — |
| Apr 30, 2026 | Crawford Amandaofficer: Chief Financial Officer | Sell | 157 | $8.03 |
| Apr 30, 2026 | Crawford Amandaofficer: Chief Financial Officer | Sell | 142 | $3.20 |
| Apr 30, 2026 | Crawford Amandaofficer: Chief Financial Officer | Sell | 140 | $4.92 |
| Apr 30, 2026 | Workman Kurtofficer: President & CEO | Grant | 850,000 | — |
| Apr 30, 2026 | Workman Kurtofficer: President & CEO | Sell | 49,056 | $8.46 |
Source: OWLT SEC Form 4 filings, latest Aug 21, 2026. For informational purposes only — not investment advice.
See the full OWLT insider & 13F page →Owlet, Inc. company profile
Overview
Owlet, Inc. (NYSE:OWLT) is a digital parenting platform company founded in 2012 and headquartered in Lehi, Utah. The company went public in November 2020 and specializes in infant health monitoring technology. Owlet has evolved from a single-product baby monitor company into a comprehensive digital health platform focused on providing real-time health data and insights to parents of infants and young children. The company has navigated significant regulatory challenges, including FDA approval processes, and has successfully transformed its business model from primarily hardware sales to include subscription services and medical device applications.
Business
Owlet operates in the infant health monitoring and digital parenting technology sector, which sits at the intersection of consumer electronics, healthcare devices, and digital health services. The company's core business revolves around wearable monitoring technology that tracks vital signs in babies and young children. The company's flagship product is the Dream Sock, a wearable baby monitor that tracks an infant's oxygen levels, heart rate, and sleep patterns. This sock-like device uses pulse oximetry technology - the same technology used in hospitals - to monitor a baby's vital signs while they sleep. The device connects to a smartphone app that provides real-time alerts and data to parents. The Dream Sock has received FDA clearance, distinguishing it from many consumer baby monitors that lack medical device approval. Owlet also offers the Dream Duo, which combines the Dream Sock with an HD video camera for comprehensive monitoring. The Cam is a standalone video streaming device that allows parents to see and hear their baby remotely. For medical applications, the company produces BabySat, an FDA-cleared prescription device designed for infants with specific medical conditions who require more intensive monitoring. A significant recent addition to Owlet's portfolio is Owlet 360, a subscription service launched in 2024 that provides personalized health insights, sleep coaching, and data analytics based on the monitoring data collected from their devices. This service represents the company's strategic pivot toward recurring revenue and value-added digital services. The company also operates Dream Lab, an interactive online platform designed to help families build healthy sleep habits through educational content and digital coaching tools. Revenue is primarily generated through hardware sales (approximately 85-90% of revenue) with the emerging subscription service representing a growing but still small portion of total revenue.
Revenue model
Owlet generates revenue through multiple channels and business models. The primary revenue source is direct product sales of hardware devices, including the Dream Sock, Dream Duo, Cam, and BabySat. These products are sold through various channels including direct-to-consumer online sales, major retailers like Amazon, Target, and Walmart, and increasingly through medical distribution channels. The company's customers fall into two main categories: consumer parents purchasing monitoring devices for peace of mind and convenience, and medical customers including hospitals, NICUs (Neonatal Intensive Care Units), and families with infants requiring medical monitoring. The consumer segment represents the majority of current revenue, while the medical segment is a growing area with higher margins and insurance reimbursement potential. A newer revenue stream is the Owlet 360 subscription service, priced at $5.99 per month, which provides enhanced features, personalized insights, and digital coaching services. With over 48,000 paying subscribers as of Q1 2025, this represents a growing recurring revenue opportunity that extends customer lifetime value beyond the initial hardware purchase. Several factors influence Owlet's profitability margins. Positive margin drivers include the company's transition from China-based manufacturing to Vietnam and Thailand, which has improved gross margins to over 50%. The FDA clearance of their devices provides competitive differentiation and pricing power. International expansion, particularly in Europe where the company has CE Medical approval, offers higher margin opportunities. The subscription service provides high-margin recurring revenue once the customer base scales. Margin pressures come from competitive pricing in the consumer electronics market, potential tariffs on manufacturing locations, marketing costs required to build brand awareness in new markets, and the substantial R&D investments needed to maintain regulatory compliance and product innovation. The company's relatively small scale compared to larger consumer electronics manufacturers also limits economies of scale in manufacturing and procurement.
Competitive moat
Owlet's competitive moat is moderate but strengthening, built primarily on regulatory approvals and brand recognition rather than technology barriers. The company's strongest defensive position comes from its FDA clearance for both the Dream Sock and BabySat devices, which creates a significant regulatory hurdle for competitors. Obtaining FDA approval requires substantial time, expertise, and financial investment, and Owlet's early success in navigating this process provides a meaningful advantage in the infant monitoring space. The company has built considerable brand recognition among parents, particularly in the United States, where it has achieved approximately 31% market share in the baby monitor category. This brand strength is reinforced by word-of-mouth marketing from satisfied customers and growing inclusion in baby registries, which increased 63% year-over-year in Q1 2025. However, Owlet's moat faces several challenges. The underlying pulse oximetry technology is not proprietary and is widely used in medical devices. Larger technology companies like Apple or Google could potentially enter this market with greater resources and existing healthcare relationships. Competition is emerging, notably from Masimo, a established medical device company that has received FDA approval for a competing infant monitor. The company's data advantage from monitoring millions of babies could potentially create network effects and improve its algorithms over time, but this advantage is still developing. International expansion and the transition to a subscription-based model with Owlet 360 could strengthen the moat by creating switching costs and customer loyalty, but these initiatives are relatively new and unproven at scale. Overall, Owlet operates in a defensible niche but lacks the strong network effects, switching costs, or proprietary technology that characterize companies with truly durable competitive advantages. The regulatory approvals provide the strongest current protection, but sustained success will depend on execution in building brand loyalty and expanding the platform's value proposition.
Risks & safety
Owlet presents a moderate margin of safety with improving but still concerning financial metrics. • **Liquidity and Solvency**: The company maintains $16.3 million in cash with a current ratio of 1.19, indicating adequate short-term liquidity. However, total liabilities of $63.4 million exceed total assets of $51.4 million, creating a negative book value situation. Free cash flow was negative $5.9 million in Q1 2025, though this represents improvement from prior periods. • **Debt Burden**: Debt-to-equity ratio of 0.73 indicates moderate leverage. The company completed debt restructuring in 2024 and has managed to reduce cash burn significantly from prior years. • **Valuation Metrics**: Trading at 4.7x earnings and 3.0x EV/EBITDA based on recent profitable quarters, the valuation appears reasonable if profitability trends continue. However, the company's history of losses and negative book value suggest caution. • **Operational Trends**: Positive adjusted EBITDA for four consecutive quarters and 43% revenue growth in Q1 2025 indicate improving operational performance. Gross margins above 50% provide cushion for operational leverage. • **Risk Factors**: Small scale, competitive market, regulatory dependency, and international expansion execution risks. Manufacturing concentration in Southeast Asia creates supply chain vulnerability.
Recent development
Over the past several years, Owlet has undergone a significant strategic transformation from a consumer electronics company to a regulated medical device and digital health platform provider. The most critical development was obtaining FDA clearance for both the Dream Sock and BabySat devices, which differentiated Owlet from unregulated consumer baby monitors and opened medical market opportunities. The company has aggressively expanded internationally, achieving CE Medical approval for 26 countries in Europe and the UK, resulting in 96-104% international revenue growth. This expansion has been a key driver of overall revenue growth and margin improvement. A major strategic pivot has been the launch of Owlet 360, a subscription service that transforms the company's business model from one-time hardware sales to recurring revenue. The service has achieved over 48,000 subscribers with strong retention rates of 85% in the first month and 60% daily active usage, indicating solid product-market fit. The company has also entered the medical distribution channel, partnering with Durable Medical Equipment (DME) providers and beginning insurance reimbursement programs in 12 Medicaid states. Notable partnerships include AdaptHealth and Children's Hospital of the King's Daughters, representing the company's push into hospital and clinical settings. Operationally, Owlet has significantly improved its cost structure, reducing operating expenses by nearly 60% and achieving positive adjusted EBITDA for four consecutive quarters. The company has also diversified its manufacturing away from China to Vietnam and Thailand, improving margins and reducing tariff exposure. These developments collectively represent Owlet's evolution from a single-product consumer company to a diversified digital health platform with medical device credentials, international reach, and recurring revenue streams.
OWLT company profile · for informational purposes only — not investment advice.
Track OWLT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free